Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis

Venetoclax (VEN) combined with azacitidine (AZA) or decitabine (DEC) has been approved for older adults with acute myeloid leukemia (AML) unfit for intensive chemotherapy based on the pivotal VIALE-A trial. However, this trial only compared AZA + VEN with AZA monotherapy. Therefore, we compared the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwag, Daehun, Cho, Byung-Sik, Bang, Su-Yeon, Lee, Jong Hyuk, Min, Gi-June, Park, Sung-Soo, Park, Silvia, Yoon, Jae-Ho, Lee, Sung-Eun, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Min, Chang-Ki, Cho, Seok-Goo, Lee, Jong Wook, Kim, Hee-Je
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760636/
https://www.ncbi.nlm.nih.gov/pubmed/36529771
http://dx.doi.org/10.1038/s41408-022-00770-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760636/
https://www.ncbi.nlm.nih.gov/pubmed/36529771
http://dx.doi.org/10.1038/s41408-022-00770-x

Ejemplares similares